Half-year report · Q2
4572.TEDINET S100U5Y7
Period2024-01-01 → 2024-06-30
Filed2024-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥316m | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Revenue | ¥1.6bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥501m | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Operating income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Operating income | −¥864m | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Ordinary income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥868m | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥869m | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥886m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Net income | −¥886m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Total assets | ¥3.7bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥4.6bn | at 2023-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥470m | at 2024-06-30 | Cons. | Liabilities |
| Total liabilities | ¥472m | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.2bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥3.9bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥4.1bn | at 2023-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.0bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.0bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥222m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥939m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥279m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.2bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-63.25 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-68.62 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-53.81 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 87.2% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.9% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 8
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥1.1bn |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥316m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥316m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥24m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥1.0bn |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥501m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥501m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥169m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 417
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 315642000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration | 315642000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | -24361000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -1070639000 | JPY |
| Operating income | CurrentYTDDuration | -1095000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-08-08 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第22期中(自 2024年1月1日 至 2024年6月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | Carna Biosciences, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 吉野公一郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00987 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45720 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Filer name in english | FilingDateInstant | Carna Biosciences, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |